|
시장보고서
상품코드
2131320
브리가티닙정 시장 규모, 점유율 및 성장 분석 : 함량별, 적응증별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Brigatinib Tablet Market Size, Share, and Growth Analysis, By Strength (30 mg, 90 mg), By Indication (ALK-Positive NSCLC, Other Oncology Indications), By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 브리가티닙정 시장 규모는 2024년에 7억 8,000만 달러로 평가되며, 2025년 8억 4,318만 달러에서 2033년까지 15억 7,227만 달러로 확대할 전망이며, 예측 기간(2026-2033년)에 CAGR 8.1%로 성장할 것으로 전망되고 있습니다.
전 세계 브리가티닙 정제 시장은 치료 저항성 비소세포폐암(NSCLC), 특히 크리조티닙 등 1세대 치료에 반응하지 않는 환자를 대상으로 하는 경구용 ALK 억제제로서의 역할이 특징입니다. 주요 성장 요인은 효과적인 2차 치료법에 대한 수요입니다. 브리가치닙은 중추신경계로의 침투성이 향상되었으며, 무악화 생존 기간을 연장하는 효과가 있기 때문입니다. 이에 따라 보험 적용 및 임상 경로에 영향을 미친 긍정적인 임상 시험 결과에 힘입어 전 세계에서 처방 건수가 증가하고 있습니다. 또한 젊은 층과 비흡연자에서 ALK 재조합 폐암의 발생률이 증가함에 따라 이용하기 쉬운 경구 요법에 대한 수요가 높아지고 있습니다. 제약사와 제네릭 의약품 제조업체 간의 제휴는 비용 절감을 목적으로 하며, 특히 신흥 시장에서 시장 보급을 촉진하는 데 기여합니다.
전 세계 브리가치닙 정제 시장의 성장 요인
ALK 양성 및 ROS1 양성 비소세포폐암에 대한 브리가티닙의 적응증 확대는 치료 가능성을 대폭 높여, 종양 전문의들이 치료 프로토콜의 더 이른 단계에서 이 약물을 도입하도록 유도하고 있습니다. 이러한 적응증 확대로 인해 의료 종사자들이 내성 기전에 대응하기 위한 효과적인 해결책을 모색함에 따라 처방률이 상승하고 있습니다. 병원, 전문 약국, 외래 클리닉에서의 본 약제 채택 확대가 시장 수요를 견인하고 있습니다. 또한 제약사가 인지도 제고를 위해 펼친 노력은 처방 의사의 신뢰를 높여 지속적인 성장을 촉진하고 있습니다. 환자 지원 단체 역시 이 약물의 우수한 안전성 프로파일을 강조하며, 표준 치료 관행에 대한 도입을 더욱 지원하고 있습니다.
전 세계 브리가치닙 정제 시장의 제약 요인
표준 화학요법에 비해 브리가티닙의 비용이 고가이기 때문에 병원 및 보험사에는 재정적 제약이 발생하고 있으며, 그 결과 약제 리스트 등재 기준이 엄격해지고 사전 승인 절차가 필요해지고 있습니다. 지불 기관은 종종 제한적인 환급 조건을 협상하므로 특히 의료 예산이 제한된 지역에서는 환자의 접근이 방해받거나 제한될 수 있습니다. 이러한 상황으로 인해 의사들은 비용 대비 효과가 더 높은 대체 약물을 고려하게 되며, 그 결과 임상적 이점이 있음에도 불구하고 처방률이 낮아져 해당 약물의 시장 침투가 저해되고 있습니다. 그 결과, 브리가티닙과 관련된 재정적 장벽은 특히 신흥 시장에서 이 약물의 광범위한 수용에 큰 장애물이 되고 있습니다.
전 세계 브리가티닙 정제 시장 동향
전 세계 브리가티닙 정제 시장에서는 포괄적인 유전체 프로파일링이 치료 프로토콜에 통합되는 것을 배경으로, 정밀 종양학으로의 뚜렷한 추세가 나타나고 있습니다. 이러한 패러다임의 변화는 특정 ALK 및 ROS1 돌연변이에 맞춘 치료법의 필요성을 강조하고 있으며, 동반 진단제에 대한 수요 증가를 촉진하는 동시에 제약 회사와 진단 서비스 제공업체 간의 전략적 제휴를 촉진하고 있습니다. 의료 시스템이 돌연변이에 기반한 치료 알고리즘에 중점을 두면서, 실시간 의사결정을 가능하게 하는 데이터 인프라에 대한 투자가 진행되고 있으며, 그 결과 환자들이 브리가티닙을 이용한 표적 치료를 더 쉽게 받을 수 있게 되었습니다. 이러한 추세는 전 세계 맞춤형 폐암 치료 경로에서 브리가티닙의 역할을 확고히 하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 브리가티닙정 시장 규모 : 함량별
세계의 브리가티닙정 시장 규모 : 적응증별
세계의 브리가티닙정 시장 규모 : 유통 채널별
세계의 브리가티닙정 시장 규모 : 최종사용자별
세계의 브리가티닙정 시장 규모 : 지역별
세계의 브리가티닙정 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSAGlobal Brigatinib Tablet Market size was valued at USD 780.0 Million in 2024 and is poised to grow from USD 843.18 Million in 2025 to USD 1572.27 Million by 2033, growing at a CAGR of 8.1% during the forecast period (2026-2033).
The global market for brigatinib tablets is characterized by the oral ALK inhibitor's role in addressing treatment-resistant non-small cell lung cancer (NSCLC), particularly for patients who do not respond to first-generation therapies such as crizotinib. A major growth driver is the demand for effective second-line treatment options, as brigatinib offers enhanced central-brain penetration and extended progression-free survival rates. This has led to increased prescriptions globally, driven by positive trial results that influenced insurance coverage and clinical pathways. Additionally, the rising incidence of ALK-rearranged lung cancer among younger, non-smoking populations amplifies the need for accessible oral therapies. Collaborations between pharmaceutical companies and generic manufacturers are aimed at reducing costs, thus facilitating greater market adoption, particularly in emerging markets.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Brigatinib Tablet market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Brigatinib Tablet Market Segments Analysis
Global brigatinib tablet market is segmented by strength, indication, distribution channel, end user and region. Based on strength, the market is segmented into 30 mg, 90 mg and 180 mg. Based on indication, the market is segmented into ALK-Positive NSCLC and Other Oncology Indications. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Cancer Centers and Specialty Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Brigatinib Tablet Market
The expansion of brigatinib's indications for treating ALK-positive and ROS1-positive non-small cell lung cancer significantly enhances its therapeutic potential, encouraging oncologists to incorporate it earlier in treatment protocols. This widened scope leads to increased prescribing rates as healthcare professionals look for effective solutions to combat resistance mechanisms. The rising adoption of this medication across hospitals, specialty pharmacies, and outpatient clinics is driving market demand. Additionally, awareness initiatives from pharmaceutical companies bolster confidence among prescribers, promoting sustained growth. Patient advocacy organizations also highlight the drug's favorable safety profile, further facilitating its integration into standard treatment practices.
Restraints in the Global Brigatinib Tablet Market
The high cost of brigatinib compared to standard chemotherapy options imposes financial constraints on hospitals and insurance companies, resulting in more stringent formulary placements and necessitating prior authorization processes. Payers frequently negotiate limited reimbursement terms, which can hinder or restrict patient access, particularly in areas with limited healthcare budgets. This circumstance leads physicians to consider more cost-effective alternatives, thereby decreasing prescription rates and hampering the drug's market penetration despite its clinical benefits. As a result, the financial barriers associated with brigatinib serve as a considerable obstacle to its widespread acceptance, particularly in burgeoning markets.
Market Trends of the Global Brigatinib Tablet Market
The Global Brigatinib Tablet market is witnessing a significant trend towards precision oncology, fueled by the integration of comprehensive genomic profiling into treatment protocols. This paradigm shift emphasizes the need for therapies tailored to specific ALK and ROS1 mutations, driving an increased demand for companion diagnostics and fostering strategic collaborations between pharmaceutical companies and diagnostic providers. As healthcare systems focus on mutation-driven treatment algorithms, investments in data infrastructure are emerging to facilitate real-time decision-making, which in turn enhances patient access to targeted brigatinib regimens. This trend solidifies brigatinib's role in personalized lung cancer care pathways across the globe.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Brigatinib Tablet Market Size by Strength & CAGR (2026-2033)
- Market Overview
- 30 mg
- 90 mg
- 180 mg
Global Brigatinib Tablet Market Size by Indication & CAGR (2026-2033)
- Market Overview
- ALK-Positive NSCLC
- Other Oncology Indications
Global Brigatinib Tablet Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Brigatinib Tablet Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Cancer Centers
- Specialty Clinics
Global Brigatinib Tablet Market Size by Region & CAGR (2026-2033)
- Market Overview
- North America
- Europe
- Asia-Pacific
- Others
Global Brigatinib Tablet Market Size & CAGR (2026-2033)
- North America (Strength, Indication, Distribution Channel, End User, Region)
- US
- Canada
- Europe (Strength, Indication, Distribution Channel, End User, Region)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Strength, Indication, Distribution Channel, End User, Region)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Strength, Indication, Distribution Channel, End User, Region)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Strength, Indication, Distribution Channel, End User, Region)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Natco Pharma Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Beacon Pharmaceuticals PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hetero Labs Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Lifesciences Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MSN Laboratories Pvt. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Laurus Labs Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurobindo Pharma Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Intas Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Accord Healthcare Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz Group AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alvogen, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Apotex Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Torrent Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Macleods Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
(주말 및 공휴일 제외)
